John Goetzinger, MD
Rheumatology · Oklahoma City, OKNPI 1174979942
Payments from drug & device makers
Across 542 payments — averaging $70.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$20K
- UCB, Inc.$6K
- AbbVie$3K
- Progentec Diagnostics, Inc.$2K
- Amgen$1K
- Johnson & Johnson$1K
- plus $4K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 1 | $20,235 |
| UCB, Inc. | 61 | $6,128 |
| AbbVie | 174 | $2,744 |
| Progentec Diagnostics, Inc. | 1 | $2,400 |
| Amgen(2 entities) | 93 | $1,388 |
| Johnson & Johnson | 44 | $1,108 |
| AstraZeneca(2 entities) | 39 | $950 |
| Novartis | 23 | $441 |
| E.r. Squibb & Sons, L.L.C. | 20 | $395 |
| GSK | 14 | $352 |
| Sanofi | 4 | $339 |
| Lilly USA, LLC | 15 | $315 |
| Genentech USA, Inc. | 17 | $300 |
| Janssen Scientific Affairs, LLC | 2 | $203 |
| Sandoz | 6 | $138 |
| Boehringer Ingelheim | 5 | $108 |
| Aurinia Pharma U.S., Inc. | 4 | $70 |
| Pfizer | 4 | $65 |
| Dexcom, Inc. | 4 | $59 |
| Fresenius Kabi USA, LLC | 3 | $51 |
| ANI Pharmaceuticals, Inc. | 3 | $49 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Organon | 2 | $26 |
| Mylan Institutional Inc. | 1 | $24 |
How this compares
$37,963 in reported general payments places this provider in the 75th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Oklahoma City
- Christine CoddingOklahoma City$2.8M
- Latisha HeinlenOklahoma City$1.9M
- Cristina ArriensOklahoma City$1.8M
- Joan MerrillOklahoma City$1.8M
- Mohammad KhanOklahoma City$999K
- Fahed HamadehOklahoma City$321K
- William SchnitzOklahoma City$290K
- Michael PickrellOklahoma City$163K
- Judith JamesOklahoma City$18K
- Robert ArthurOklahoma City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.